Specifically, Defendants made false and / or misleading statements and / or failed to disclose that: (i) Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius» acquisition of Akorn; (ii) the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Akorn shares traded at artificially
inflated prices
during the
Class Period, and class members suffered significant losses and dam
Class Period, and
class members suffered significant losses and dam
class members suffered significant losses and damages.